|Bid||18.71 x 800|
|Ask||23.00 x 800|
|Day's Range||18.23 - 18.60|
|52 Week Range||17.93 - 38.39|
|PE Ratio (TTM)||N/A|
|Beta (3Y Monthly)||0.00|
|Expense Ratio (net)||0.99%|
Big pharmaceutical companies were on the hot seat at Capitol Hill today with CVS Health, Cigna, Prime Therapeutics, Humana, and UnitedHealthcare's OptumRx testifying before the Senate Finance Committee on the rising cost of prescription drugs. Among the topics discussed included rebates paid by drug makers contributing to the high costs and the drug industry's pursuit of profits--all to shift the blame from the pharmaceutical companies to the drug makers. U.S. President Donald Trump has already lambasted the pharmaceutical industry for the rising costs associated with prescription drugs.
The Daily Pharmaceutical & Medical Bull 3X Shares (PILL) gained 1.35 percent on news that General Electric will sell its biopharmaceutical business to conglomerate company Danaher for $21.4 billion. The sale comes as GE CEO Larry Culp is looking to take the company out of its worst slump in its 127-year history.
According to a report by the Silicon Valley Bank, biopharma deals in 2018 totaled $49 billion and more mergers in 2019 could continue providing growth in the industry, fueling ETFs like Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and Direxion Daily S&P Biotech Bull 3X ETF (LABU) . This was evident early in the new year as the biopharma space began 2019 with Bristol-Myers Squibb offering $74 billion to take over Celgene--a deal that could allow Bristol to become a top five pharmaceutical giant. RBC Capital Markets analyst Brian Abrahams said there's "a strong need to diversify around maturing franchises with (patents expiring) and biotech valuations having come down.
Healthcare ETFs have been displaying positive momentum. Traders looking to bolster that healthcare momentum profile can consider leveraged ETFs, such as the Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL) . There are other catalysts to consider, including that the U.S. economy is moving into the late-cycle phase, overall growth may slow and signs of an economic slowdown could pop up.
With markets jittery about tariffs and trade wars, investors considering sector-level ideas may want to lean toward groups that generate significant portions of their revenue on a domestic basis. The healthcare ...
The prices of drugs are rising and while this may not be welcome news for patients, it's the perfect elixir for pharmaceutical-focused ETFs to generate profits to help investors cure ailing portfolios and in the case of the Daily Pharmaceutical & Medical Bull 3X Shares (PILL) , it could provide three times the prescription strength. In the year-to-date chart, PILL has made a move above its 50-day moving average since mid-May and the success of PI could largely depend on whether government intervenes to cut drug prices. U.S. President Donald Trump is already lambasting the pharmaceutical industry for the rising costs associated with prescription drugs, notably his criticism of pharmaceutical giant Pfizer.
The rising prices of drug treatments, more dependence on immuno-oncology and mergers focused on mid-sized biotech company acquisitions are just a few factors spurning the growth in the biotechnology and pharmaceuticals industry, giving ETFs like Daily Pharmaceutical & Medical Bull 3X Shares (PILL) and Direxion Daily S&P Biotech Bull 3X ETF (LABU) exceptional returns. PILL seeks investment results equal to 300% of the daily performance of the Dynamic Pharmaceutical Intellidex Index and concentrates its allocations towards securities of the index and other financial instruments that provide daily leveraged exposure to the index. The index itself just matched a previous high and PILL itself is posting year-to-date returns of 6.36% according to performance figures from Yahoo! Finance.